The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
Open accessAbstract
Background Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries.Methods We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000-07 and the corresponding time trends during 1995-2007. Incidence was calculated as the number of new cases divided by the corresponding total person-years in the population. 5-year relative survival was calculated by the Ederer-2 method. Seven registries (Belgium, Bulgaria, Finland, Ireland, the Netherlands, Slovenia, and the Navarra region in Spain) provided additional data for hospitals treating about 220 000 cases diagnosed in 2000-07. We also calculated hospital volume admission as the number of treatments provided by each hospital rare cancer group sharing the same referral pattern.Findings Rare cancers accounted for 24% of all cancers diagnosed in the EU during 2000-07. The overall incidence rose annually by 0.5% (99·8% CI 0·3-0·8). 5-year relative survival for all rare cancers was 48·5% (95% CI 48·4 to 48·6), compared with 63·4% (95% CI 63·3 to 63·4) for all common cancers. 5-year relative survival increased (overall 2·9%, 95% CI 2·7 to 3·2), from 1999-2001 to 2007-09, and for most rare cancers, with the largest increases for haematological tumours and sarcomas. The amount of centralisation of rare cancer treatment varied widely between cancers and between countries. The Netherlands and Slovenia had the highest treatment volumes.Interpretation Our study benefits from the largest pool of population-based registries to estimate incidence and survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk factors, improved diagnosis, and registration problems. Survival could be improved by early diagnosis, new treatments, and improved case management. The centralisation of treatment could be improved in the seven European countries we studied.Funding The European Commission (Chafea).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, translating the capabilities of current patch-based foundation models to address patient- and slide-level clinical challenges still remains complex due to the immense scale of gigapixel WSIs, compounded by the small size of patient cohorts in real-world evidence39–42, especially for rare diseases with limited training data43–45.”
From A multimodal whole-slide foundation model for pathology (2025) · cites this paper as [43]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,810
Angelis, R. D., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., Trama, A., Visser, O. J., Brenner, H., Ardanáz, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70546-1 · Cited by 1,888
Self-citationWorldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis
Vaccarella, S., Franceschi, S., Bray, F., Wild, C. P., Plummer, M., & Dal Maso, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1604412 · Cited by 1,145
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Tos, A. P. D., Kunkler, I. H., Otter, R., Licitra, L. F., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 813
Self-citationHuman papillomavirus related head and neck cancer survival: A systematic review and meta-analysis
O’Rorke, M. A., Ellison, M. V., Murray, L., Moran, M., James, J. A., & Anderson, L. A. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.019 · Cited by 422
Self-citationHeck, J. E., Berthiller, J., Vaccarella, S., Winn, D. M., Smith, E., Shangina, O., Schwartz, S. M., Purdue, M. P., Pilarska, A., Eluf‐Neto, J., et al. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp350 · Cited by 385
Recent changes in the epidemiology of head and neck cancer
Curado, M. P., & Hashibe, M. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832a68ca · Cited by 354
Kantarjian, H. M., O'Brien, S. M., Jabbour, E. J., Garcia‐Manero, G., Quintás‐Cardama, A., Shan, J., Rios, M. B., Ravandi, F., Faderl, S. H., Kadia, T. M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-358135 · Cited by 335
Sant, M., Minicozzi, P., Mounier, M., Anderson, L. A., Brenner, H., Holleczek, B., Marcos‐Gragera, R., Maynadié, M., Monnereau, A., Osca‐Gelis, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70282-7 · Cited by 292
Self-citationLepage, C., Capocaccia, R., Hackl, M., Lemmens, V., Molina‐Montes, E., Pierannunzio, D., Sant, M., Trama, A., Faivre, J., Hackl, M., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.034 · Cited by 149
Self-citation
Research works printed but not linked: 1
- Ederer, 1961, The relative survival: a statistical methodology, Natl Cancer Inst Monogr, 6, 101
Cited by
Sorted by citations
Items 101–200 of 517
Vos, M., Grünhagen, D. J., Koseła-Paterczyk, H., Rutkowski, P. L., Sleijfer, S., & Verhoef, C. K. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.04.004 · Cited by 19
Delay in Diagnosis and Treatment of Bone Sarcoma—Systematic Review
Ciechanowicz, D., Kotrych, D., Starszak, K., Prowans, P., Zacha, S., Kamiński, A., Brodecki, A., & Kotrych, K. (2025) · Cancers · doi:10.3390/cancers17060981 · Cited by 18
Updates on Treatments and Management of Nasopharyngeal Carcinoma
Chua, M. L. K., Zhang, X., Wong, K. C. W., Marret, G., Spreafico, A., & Ma, B. B. Y. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472460 · Cited by 19
Epidemiology of Rare Cancers in India and South Asian Countries - Remembering the Forgotten
Mailankody, S., Bajpai, J., Budukh, A. M., Swaminathan, R., Dikshit, R. P., Dhimal, M., Perera, S., Tshomo, U., Bagal, S. S., Bhise, M. D., et al. (2022) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2023.100168 · Cited by 18
Self-citationThe Lived Experience of Persons With Malignant Pleural Mesothelioma in the United States
Walker, S. L., Crist, J. D., Shea, K., Holland, S., & Cacchione, P. Z. (2019) · Cancer Nursing · doi:10.1097/ncc.0000000000000770 · Cited by 18
The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
Satake, T., Morizane, C., Rikitake, R., Higashi, T., Okusaka, T., & Kawai, A. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01920-5 · Cited by 18
Toxicities in long‐term survivors of head and neck cancer—A multi‐national cross‐sectional analysis
Taylor, K., Amdal, C. D., Bjordal, K., Astrup, G. L., Herlofson, B. B., Duprez, F., Gama, R. R., Jacinto, A. A., Hammerlid, E. B., Scricciolo, M., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70033 · Cited by 17
Nagel, G., Bjørge, T., Jaensch, A., Peter, R. S., Häggström, C., Lang, A. H., Engeland, A., Teleka, S., Jirström, K., Lindquist, D., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33530 · Cited by 17
Li, Y., Wu, G., Zhang, Y., Yang, W., Wang, X., Duan, L., Niu, L., Chen, J., Zhou, W., Liu, J., et al. (2022) · Frontiers in Oncology · doi:10.2139/ssrn.4012587 · Cited by 17
Zhang, L., Wang, W., Chen, J., Feng, J., Liao, Y.-Z., Zou, Y. F., & Liu, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-56738-3 · Cited by 17
Sant, M., Vener, C., Lillini, R., Rossi, S., Bonfarnuzzo, S., Marcos-Gragera, R., Maynadié, M., Innos, K., Paapsi, K., Visser, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00141-4 · Cited by 17
Self-citationZhang, L., Akiyama, T., Fukushima, T., Iwata, S., Tsuda, Y., Takeshita, K., Kawai, A., Tanaka, S., & Kobayashi, H. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab033 · Cited by 17
Remón, J., Bernabé, R., Diz, P., Felip, E., González-Larriba, J. L., Lázaro, M., Mielgo-Rubio, X., Sánchez, A., Sullivan, I., & Massutti, B. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02788-w · Cited by 17
Rare cancer and return to work: experiences and needs of patients and (health care) professionals
Olischläger, D. L. T., den Boer, L. X. Y., de Heus, E., Brom, L., Dona, D. J. S., Klümpen, H., Stapelfeldt, C. M., & Duijts, S. F. A. (2022) · Disability and Rehabilitation · doi:10.1080/09638288.2022.2099589 · Cited by 17
Crimì, A., Binitie, O. T., Crimì, F., Letson, G. D., & Joyce, D. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237111 · Cited by 16
Martínez‐Trufero, J., Jurado, J. C., Gómez-Mateo, M. C., Bernabéu, D., Floría, L. J., Lavernia, J., Sebio, A., del Muro, X. G., Alvarez, R. M., Correa, R., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102259 · Cited by 16
Jakob, J., Andreou, D., Bedke, J., Denschlag, D., Dürr, H. R., Frese, S., Gösling, T., Graeter, T. P., Grünwald, V., Grützmann, R., et al. (2023) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-023-03002-3 · Cited by 15
The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review
Vivelo, C. A., Reilly, K. M., Widemann, B. C., Wedekind, M. F., Painter, C., O'Neill, A. F., Mueller, S., Elemento, O., Gross, A. M., & Sandler, A. B. (2023) · The Oncologist · doi:10.1093/oncolo/oyad285 · Cited by 15
Lenoci, D., Resteghini, C., Serafini, M. S., Pistore, F., Canevari, S., Ma, B. B. Y., Cavalieri, S., Alfieri, S., Trama, A., Licitra, L. F., et al. (2023) · Translational research · doi:10.1016/j.trsl.2023.10.004 · Cited by 15
Self-citationde Back, T. R., Linssen, J. D. G., van Erning, F. N., Verbakel, C. S. E., Schafrat, P. J. M., Vermeulen, L., de Hingh, I. H. J. T., & Sommeijer, D. W. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113529 · Cited by 16
Organoid drug profiling identifies methotrexate as a therapy for SCCOHT, a rare pediatric cancer
Kim, S., de Weert, T. A. E., Vermeulen, M. A., Ringnalda, F. C. A. S., Kester, L. A., Zsíros, J., Eising, S., Molenaar, J. J., Sanders, K., van de Wetering, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq1724 · Cited by 15
Omics-driven drug repurposing as a source of innovative therapies in rare cancers
Pantziarka, P., & Meheus, L. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1500690 · Cited by 15
International travel to obtain medical treatment for primary retinoblastoma: A global cohort study
Bowman, R. J. C., Foster, A., Stacey, A. W., Keren‐Froim, N., Bascarán, C., Kivelä, T., Munier, F. L., & Fabian, I. D. (2020) · International Journal of Cancer · doi:10.1002/ijc.33350 · Cited by 15
Fonseca, A., Lobo, J., Hazard, F. K., Gell, J. J., Nicholls, P. K., Weiss, R. S., Klosterkemper, L., Volchenboum, S. L., Nicholson, J. C., Frazier, A. L., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02000-4 · Cited by 15
Remón, J., Bironzo, P., Girard, N., Bigay-Game, L., Juan, Ó., de Castro, J., Reguart, N., Greillier, L., Cousin, S., Dansin, É., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00300-6 · Cited by 14
Debien, V., Vignot, S., Massard, C., Malouf, G. G., Hollebecque, A., Scoazec, J., Michiels, S., & Verlingue, L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103888 · Cited by 14
van Kouswijk, H. W., van Keeken, H. G., Ploegmakers, J. J. W., Seeber, G. H., & van den Akker‐Scheek, I. (2023) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-023-06315-y · Cited by 17
Enhancing Healthcare for Sarcoma Patients: Lessons from a Diagnostic Pathway Efficiency Analysis
Elyes, M., Heesen, P., Schelling, G., Bode‐Lesniewska, B., Studer, G., & Fuchs, B. (2023) · Cancers · doi:10.3390/cancers15194892 · Cited by 14
Brain metastases of sarcoma: a rare phenomenon in rare tumours
Jędrys, W., Leśniak, A., Borkowska, A. M., Rutkowski, P. L., & Sobczuk, P. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05451-1 · Cited by 16
Bayesian estimates of the incidence of rare cancers in Europe
Botta, L., Capocaccia, R., Trama, A., Herrmann, C., Salmerón, D., Angelis, R. D., Mallone, S., Bidoli, E., Marcos‐Gragera, R., Dudek-Godeau, D., et al. (2018) · Cancer Epidemiology · doi:10.1016/j.canep.2018.04.003 · Cited by 14
Self-citationPreclinical rare cancer research to inform clinical trial design
Barker, H. E., & Scott, C. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0172-2 · Cited by 14
Revolutionizing care for rare genitourinary tumours
Necchi, A., Pederzoli, F., Bandini, M., & Spiess, P. E. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00402-8 · Cited by 14
Histopathologic challenges: The second OPINION issue
Antonio Lopez-beltran, B., Canas‐Marques, R., Liang Cheng, C., & Montironi, R. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.09.003 · Cited by 14
Editorial: Special issue on rare cancers
Sandler, A. B., Reilly, K. M., & Widemann, B. C. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100774 · Cited by 14
Is There Still a Place for Brachytherapy in the Modern Treatment of Early-Stage Oral Cancer?
Tuček, L., Vošmik, M., & Petera, J. (2022) · Cancers · doi:10.3390/cancers14010222 · Cited by 13
Trama, A., Licitra, L. F., Cavalieri, S., Bonfarnuzzo, S., Baili, P., Ciarfella, A., Arias, P. P., Almadori, G., Ansarin, M., Bacigalupo, A., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283071 · Cited by 13
Self-citationSinonasal malignancies: Histopathological entities, regional involvement and long-term outcome
Anschuetz, L., Hohenberger, R., Käcker, C., Eliçin, O., Giger, R., & Caversaccio, M. D. (2023) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-023-00627-8 · Cited by 13
Liu, H., Stanworth, S. J., McPhail, S., Bishton, M. J., Rous, B., Bacon, A., & Coats, T. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013102 · Cited by 13
Padilla, C. S., Bergerot, C. D., Dijke, K., Roets, E., Boková, G., Innerhofer, V., Sodergren, S. C., Mancari, R., Bergamini, C., Way, K. M., et al. (2025) · Cancers · doi:10.3390/cancers17030387 · Cited by 13
Rare cancers in Japan: definition, clinical features and future perspectives
Kawai, A., Higashi, T., Shibata, T., Yoshida, A., Katoh, Y., Fujiwara, Y., & Nishida, T. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa121 · Cited by 13
Ooms, M., Ponke, L., Puladi, B., Winnand, P., Heitzer, M., Katz, M. S., Hölzle, F., & Modabber, A. (2022) · Head & Neck · doi:10.1002/hed.27014 · Cited by 13
Wright, C. M., Halkett, G. K. B., Smith, R. C., & Moorin, R. E. (2020) · BMC Cancer · doi:10.1186/s12885-020-07103-w · Cited by 13
Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
Krendyukov, A., Singhvi, S., & Zabransky, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.636561 · Cited by 12
Impact of retroperitoneal tumors on the digestive tract (Review)
Marcu, D., Iorga, L., Diaconu, C. C., Bratu, O. G., BUNGAU, S. G., Bălescu, I., Bacalbaşa, N., & Radu, F. I. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11647 · Cited by 12
Clinical-proteomic classification and precision treatment strategy of chordoma
Yin, H., Hu, J., Gao, J., Su, T., Jin, J., Jiang, C., Yin, W., Xu, X., Chang, Z., Sun, W., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101757 · Cited by 12
Garcia-Velasco, A., Zacarías‐Pons, L., Teixidor, H., Valeros, M. N., Liñan, R., Carmona-Garcia, M. C., Puigdemont, M., Carbajal, W., Guardeño, R., Malats, N., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249538 · Cited by 12
Self-citationSobiborowicz, A., Spalek, M. J., Czarnecka, A. M., & Rutkowski, P. L. (2021) · Cancer Control · doi:10.1177/1073274820983028 · Cited by 12
Overview of Adult Sarcoma Burden and Clinical Pathways in Brazil
David, B. B. L., de Mello, C. A. L., Thuler, L. C. S., & de Melo, A. C. (2022) · JCO Global Oncology · doi:10.1200/go.21.00387 · Cited by 12
Minot-This, M.-S., Boudou‐Rouquette, P., Jouinot, A., Percin, S. D., Balakirouchenane, D., Khoudour, N., Tlemsani, C., Chauvin, J., Thomas‐Schoemann, A., Goldwasser, F., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061224 · Cited by 12
van Dongen, J., de Heus, E., Eickholt, L., Schrieks, M., Zantingh, I., Brouwer, O. R., Oonk, M. H. M., Grotenhuis, B. A., Ezendam, N. P. M., & Duijts, S. F. A. (2022) · European Journal of Cancer Care · doi:10.1111/ecc.13676 · Cited by 12
Proteomic profiling of canine fibrosarcoma and adjacent peritumoral tissue
Beebe, E., Pöschel, A., Kunz, L., Wolski, W., Motamed, Z., Meier, D., Guscetti, F., Nolff, M. C., & Markkanen, E. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100858 · Cited by 12
Benchmarking Time-to-Treatment Initiation in Sarcoma Care Using Real-World-Time Data
Schärer, M., Heesen, P., Bode‐Lesniewska, B., Studer, G., & Fuchs, B. (2023) · Cancers · doi:10.3390/cancers15245849 · Cited by 12
Genomic-guided precision therapy for soft tissue sarcoma
Chen, H.-W., & Chen, T. W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000626 · Cited by 12
Boroujeni, M. B., Peidayesh, F., Pirnia, A., Boroujeni, N. B., Ahmadi, S. A. Y., & Gholami, M. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.10.01 · Cited by 12
Rare cancers: A network for better care
Sandrucci, S., & Gatta, G. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.06.028 · Cited by 12
Self-citationJoneborg, U., Bergamini, A., Wallin, E., Mangili, G., Solheim, O., Marquina, G., Casado, A., Rokkones, E., Coulter, J., Lok, C. A. R., et al. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004599 · Cited by 11
Measuring health-related quality of life in solid rare cancer patients: A study protocol
Padilla, C. S., Tesselaar, M. E. T., van der Graaf, W. T. A., & Husson, O. (2023) · Rare · doi:10.1016/j.rare.2023.100012 · Cited by 11
Mayo‐Yáñez, M., Klein‐Rodríguez, A., López-Eiroa, A., Cabo‐Varela, I., Rivera-Rivera, R., & Arias, P. P. (2024) · Healthcare · doi:10.3390/healthcare12060652 · Cited by 11
Zhao, D., Gao, Z., Si, M., Hu, R., Ma, X., Liu, K., Zhao, Y., He, Q., Kong, X., Jia, C., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.155072 · Cited by 11
Epigenetics of Thymic Epithelial Tumors
Nicolì, V., & Coppedè, F. (2023) · Cancers · doi:10.3390/cancers15020360 · Cited by 11
Simons, B., Hillen, M. A., Aarts, J. W. M., Tromp, J. M., de Heus, E., & Duijts, S. F. A. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-023-01531-w · Cited by 11
The solitary versus supported experience: Care inequality between rare and common cancer patients
de Heus, E., van de Camp, K., Driehuis, E., van der Zwan, J. M., van Herpen, C. M. L., Merkx, M. A. W., & Duijts, S. F. A. (2023) · Psycho-Oncology · doi:10.1002/pon.6216 · Cited by 10
The prediagnostic general practitioner care of sarcoma patients: A real‐world data study
Holthuis, E. I., van der Graaf, W. T. A., Drabbe, C., van Houdt, W. J., Schrage, Y. M., Hartman, T. O., Uijen, A. A., Bos, I., Heins, M. J., Husson, O., et al. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27757 · Cited by 10
Incidence and survival of rare adult solid cancers in Europe (EUROCARE-6): A population-based study
Trama, A., Bernasconi, A., Cañete, A., Carulla, M., Daubisse‐Marliac, L., Rossi, S., Angelis, R. D., Sanvisens, A., Katalinic, A., Paapsi, K., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115147 · Cited by 10
Self-citationGlobal patterns and burden of soft tissue and extraosseous sarcomas: trends from 1990 to 2021
Zhu, M., Zhang, L., Wei, Y., Wang, X., Qin, S., Wang, T., Xu, X., & Zhou, X. Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14136-6 · Cited by 10
Prades, J., Weinman, A., Cam, Y. L., Trama, A., Frezza, A. M., & Borràs, J. M. (2020) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2020.100222 · Cited by 10
Self-citationEfficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review
Petrelli, F., Consoli, F., Ghidini, A., Perego, G., Luciani, A., Mercurio, P., Berruti, A., & Grisanti, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720748 · Cited by 10
Kasper, B., Schuster, K., Wilson, R., Bickley, S., Blay, J., Reinke, D. K., Wartenberg, M., & Haas, R. L. (2022) · Cancers · doi:10.3390/cancers14040854 · Cited by 10
Geographical and spatial disparities in the incidence and survival of rare cancers in Australia
Dasgupta, P., Cameron, J. K., Cramb, S. M., Trevithick, R., Aitken, J. F., Mengersen, K. L., & Baade, P. D. (2022) · International Journal of Cancer · doi:10.1002/ijc.34395 · Cited by 10
Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study
Pellegrini, I., Drabbe, C., Grünhagen, D. J., van de Sande, M. A. J., de Haan, J. J., Keymeulen, K., Bonenkamp, J. J., van der Graaf, W. T. A., & Husson, O. (2022) · Cancers · doi:10.3390/cancers14246099 · Cited by 10
Devi, G. R., Fish, L. J., Bennion, A., Sawin, G., Weaver, S. M., Reddy, K., Saincher, R., & Tran, A. N. (2023) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2023.102519 · Cited by 10
Lavernia, J., Claramunt, R., Romero, I., López‐Guerrero, J. A., Llombart-Bosch, A., & Machado, I. (2024) · Cancers · doi:10.3390/cancers16020432 · Cited by 10
Gouthamchand, V., Choudhury, A., Hoebers, F. J. P., Wesseling, F. W. R., Welch, M. L., Kim, S., Kaźmierska, J., Dekker, A. L. A. J., Haibe‐Kains, B., van Soest, J., et al. (2024) · BJR|Artificial Intelligence · doi:10.1093/bjrai/ubae005 · Cited by 10
Kostadinov, K. R., Popova-Sotirova, I., Marinova, Y., Мусурлиева, Н., Iskrov, G. G., & Stefanov, R. S. (2024) · Cancers · doi:10.3390/cancers16081489 · Cited by 10
Gender Differences in Sinonasal Cancer Incidence: Data from the Italian Registry
Binazzi, A., Marzio, D. D., Mensi, C., Consonni, D., Miligi, L., Piro, S., Zajacovà, J., Sorasio, D., Galli, P., Camagni, A., et al. (2024) · Cancers · doi:10.3390/cancers16112053 · Cited by 10
GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours
Rico, M., Flamarique, S., Casares, C., García, T., López, M., Martínez, M., Serrano, J., Blanco, M., Hernánz, R., Barón, L. D. I., et al. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.195 · Cited by 10
Werner, R. N., Gaskins, M. D., VALLE, G. L. A., Budach, V., Koswig, S., Mosthaf, F., Raab, H.-R., Rödel, C. M., Nast, A., Siegel, R., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.01.031 · Cited by 10
Zhao, P., Chang, J., Chen, Y.-J., Sun, X., Ma, X., Zhou, C., Zhou, L., Wang, Y., & Yang, Y. (2024) · Phenomics · doi:10.1007/s43657-023-00132-y · Cited by 9
Du, R. F., Carbonell, E. L., Huang, J., Liu, S., Wang, X., Shen, D. G., & Ke, J. (2025) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2025.3551913 · Cited by 10
Hering, K., Kuhnt, T., Kossack, N., Richter, L. M., Schultze, M., Osowski, U., Henkel, L., Gaupel, A., Solbes, M.-N., Żołyniak, B., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1547311 · Cited by 9
Prospective evaluation of genomics-guided off-label treatment
Verkerk, K., Spiekman, A. C., Mohammad, S. F. H., Verbeek, F. A. J., Timmer, H. J. L., van Maren, M. A., Zeverijn, L. J., Geurts, B. S., van der Noort, V., Roepman, P., et al. (2026) · Nature · doi:10.1038/s41586-026-10405-x · Cited by 9
A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases
do Brito, J. S., Lopes-Brás, R., Abrunhosa-Branquinho, A. N., Fernandes, I., Gomes, I., Casimiro, S., & Costa, L. (2022) · Cancers · doi:10.3390/cancers14040893 · Cited by 10
Driehuis, E., de Heus, E., Schrieks, M., Engelen, V., Buffart, T. E., Vink, G. R., & Duijts, S. F. A. (2022) · Journal of Cancer Survivorship · doi:10.1007/s11764-022-01324-7 · Cited by 9
Prognostic factors in surgically treated malignant salivary gland tumors
Hofmann, E., Priebe, J., Rieke, D. T., Doll, C., Coordes, A., Olze, H., Hofmann, V. M., Heiland, M., & Beck-Broichsitter, B. E. (2023) · Oral Oncology · doi:10.1016/j.oraloncology.2023.106484 · Cited by 9
Pierannunzio, D., Maraschini, A., López, T., Donati, S., Amodio, R., Bianconi, F., Bruni, R., Castaing, M., Cirilli, C., Fantaci, G., et al. (2023) · Cancers · doi:10.3390/cancers15174305 · Cited by 9
Self-citationPeng, C., Xie, X., Knoedler, S. A., Mi, B., & Liu, G. (2023) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-023-04105-9 · Cited by 9
Mizoguchi, N., Kano, K., Okuda, T., Koge, H., Shima, S., Tsuchida, K., Takakusagi, Y., Kawashiro, S., Yoshida, M., Kitani, Y., et al. (2024) · Cancers · doi:10.3390/cancers16152625 · Cited by 10
Panzuto, F., Barbi, S., Trama, A., & Fazio, N. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102998 · Cited by 9
Self-citationGalli, G., Trama, A., Abate-Daga, L., Brambilla, M., Garassino, M. C., & Fabbri, A. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.007 · Cited by 9
Self-citationPatel, S., Snyderman, C. H., Müller, S. K., Agaimy, A., & Seethala, R. R. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03359-8 · Cited by 9
Du, X., Zhang, C., Yin, C., Wang, W., Yan, X., Xie, D., Zheng, X., Qichang, Z., Li, M., & Song, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633899 · Cited by 9
Walking, Writing and Performance: Autobiographical Texts
Heddon, D. E., Lavery, C., & Smith, P. J. (2009) · Cited by 9
Prediction tools for the personalized management of soft-tissue sarcomas of the extremity
Acem, I., & van de Sande, M. A. J. (2022) · The Bone & Joint Journal · doi:10.1302/0301-620x.104b9.bjj-2022-0647 · Cited by 9
Botta, L., Matsuda, T., Charvat, H., Chiang, C., Lee, W., van Gestel, A. J., Martin, F. J., Geleijnse, G., Cellamare, M., Bonfarnuzzo, S., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1219111 · Cited by 8
Self-citationBoulouta, A., Kyriazoglou, A. I., Kotsantis, I., Economopoulou, P., Anastasiou, M., Pantazopoulos, A., Kyrkasiadou, M., Moutafi, M. K., Gavrielatou, N., Zazas, E., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102820 · Cited by 8
An Evaluation of Rare Cancer Policies in Europe: A Survey Among Healthcare Providers
Kostadinov, K. R., Iskrov, G. G., Мусурлиева, Н., & Stefanov, R. S. (2025) · Cancers · doi:10.3390/cancers17020164 · Cited by 8
Ashton, E., Taly, V., Tlemsani, C., Boudou, P., Percin, S. D., Noel, J., Gaudet-Chardonnet, A., Sullo, F. G., Parfait, B., Abdelli, J., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0134 · Cited by 8
Gatta, G., Luttmann, S., Trama, A., Rossi, S., Galcerán, J., Innos, K., Guevara, M., Licitra, L. F., Bennet, D., Redondo‐Sánchez, D., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115692 · Cited by 8
Self-citationTreatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours
Lykoudis, P. M., Partelli, S., Muffatti, F., Caplin, M. E., Falconi, M., Fusai, G., Hackl, M., Eycken, E. V., Henau, K., Dimitrova, N., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.08.019 · Cited by 8
Self-citationOutani, H., Hamada, K., Yasuda, N., Ueda, T., Myoui, A., Yoshikawa, H., & Okada, S. (2021) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2021.03.013 · Cited by 8
Metadata
- Authors
- Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E., Comber, H., Dimitrova, N., Leinonen, M. K., Siesling, S., van der Zwan, J. M., Van Eycken, L., Visser, O., Žakelj, M. P., Anderson, L. A., Bella, F., Kaire, I., Otter, R., Stiller, C. A., Trama, A., Hackl, M., Henau, K., Van Damme, N., Valerianova, Z., Sekerija, M., Dušek, L., Mägi, M., Paapsi, K., Malila, N., Velten, M., Troussard, X., Bouvier, V., Guizard, A.-V., Bouvier, A.-M., Arveux, P., Maynadié, M., Woronoff, A.-S., Robaszkiewicz, M., Baldi, I., Monnereau, A., Tretarre, B., Colonna, M., Molinié, F., Bara, S., Schvartz, C., Lapôtre-Ledoux, B., Grosclaude, P., Stabenow, R., Luttmann, S., Nennecke, A., Engel, J., SchubertFritschle, G., Heidrich, J., Holleczek, B., Jónasson, J. G., Clough-Gorr, K., Mazzoleni, G., Giacomin, A., Sardo, A. S., Barchielli, A., Serraino, D., Collarile, P., Pannozzo, F., Ricci, P., Autelitano, M., Spagnoli, G., Fusco, M., Usala, M., Vitale, F., Michiara, M., Tumino, R., Mangone, L., Falcini, F., Ferretti, S., Filiberti, R. A., Marani, E., Caiazzo, A. L., Iannelli, A., Sensi, F., Piffer, S., Gentilini, M., Madeddu, A., Colanino, A. Z., Maspero, S., Candela, P., Stracci, F., Tagliabue, G., Rugge, M., Baili, P., Minicozzi, P., Sant, M., Tereanu, C., Francisci, S., Tavilla, A., Pierannunzio, D., Rossi, S., Santaquilani, M., Knijn, A., Pildava, S., Smailyte, G., Calleja, N., Agius, D., Johannesen, T. B., Rachtan, J., Gózdz, S., Blaszczyk, J., Kepska, K., Lacerda, G. F. D., Bento, M. J., Miranda, A., Diba, C. S., Žagar, T., Almar, E., Larrañaga, N., Munain, A. L. D., Torrella-Ramos, A., García, J. M. D., Marcos-Gragera, R., Sanchez, M. J., Navarro, C., Salmeron, D., Moreno-Iribas, C., Galceran, J., Carulla, M., Mousavi, M., Bouchardy, C., Ess, S. M., Bordoni, A., Konzelmann, I., Rashbass, J., Gavin, A., Brewster, D. H., Huws, D. W., Ho, V. K., & Benhamou, E.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Istituto Superiore di Sanità (IT)
- National Cancer Registry (IE)
- Finnish Cancer Registry (FI)
- Netherlands Comprehensive Cancer Organisation (NL)
- Institute of Oncology Ljubljana (SI)
- Queen's University Belfast (GB)
- Policlinico Universitario di Catania (IT)
- Institut Scientifique de Santé Publique (BE)
- Public Health England (GB)
- Instituto de Salud Pública de Navarra (ES)
- Corresponding author
- Gatta, Gemma
- ORCID
- Gatta, Gemma
- Capocaccia, Riccardo
- Botta, Laura
- Mallone, Sandra
- Comber, Harry
- Dimitrova, Nadya
- Leinonen, Maarit K
- Siesling, Sabine
- Visser, Otto
- Anderson, Lesley A
- Stiller, Charles A
- Trama, Annalisa
- Dušek, Ladislav
- Mägi, Margit
- Paapsi, Keiu
- Malila, Nea
- Troussard, Xavier
- Guizard, Anne-Valérie
- Bouvier, Anne-Marie
- Arveux, Patrick
- Maynadié, Marc
- Woronoff, Anne-Sophie
- Robaszkiewicz, Michel
- Baldi, Isabelle
- Monnereau, Alain
- Colonna, Marc
- Molinié, Florence
- Grosclaude, Pascale
- Luttmann, Sabine
- Nennecke, Alice
- Mazzoleni, Guido
- Serraino, Diego
- Vitale, Francesco
- Tumino, Rosario
- Falcini, Fabio
- Ferretti, Stefano
- Filiberti, Rosa Angela
- Piffer, Silvano
- Tagliabue, Giovanna
- Rugge, Massimo
- Baili, Paolo
- Minicozzi, Pamela
- Sant, Milena
- Francisci, Silvia
- Tavilla, Andrea
- Pierannunzio, Daniela
- Rossi, Silvia
- Santaquilani, Mariano
- Knijn, Arnold
- Pildava, Santa
- Calleja, Neville
- Rachtan, Jadwiga
- Miranda, Ana
- Žagar, Tina
- Almar, Enrique
- Larrañaga, Nerea
- García, José María Díaz
- Navarro, Carmen
- Bouchardy, Christine
- Ess, Silvia M.
- Gavin, Anna
- Brewster, David H
- Huws, Dyfed Wyn
- Ho, Vincent KY
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 18
- Issue
- 8
- Pages
- 1022-1039
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2729284305
- Cited by
- 516
- References
- 22
- Citations by year
- 2026: 60 · 2025: 82 · 2024: 81 · 2023: 71 · 2022: 64 · 2021: 52 · 2020: 47 · 2019: 27 · 2018: 24 · 2017: 6
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-08-01)
- Open access
- bronze
- doi.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, other-oa)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- European Commission through the Consumers, Health, Agriculture and Food Executive Agency (Grant No. 2000111201)
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advances in Oncology and Radiotherapy
- Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
- Keywords
- rare tumor, cancer incidence, cancer survival, cancer registry, incidence trends, sarcoma, Europe, referral patterns, healthcare resource allocation, cancer care costs
- MeSH terms
- Cancer Care Facilities, Delivery of Health Care, Europe, Female, Hospitalization, Humans, Male, Neoplasms, Registries, Incidence, Survival Rate, Rare Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
